Heron Therapeutics (HRTX)

Heron Therapeutics Stock Price & Analysis


HRTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.19 - $12.79
Previous Close$3.86
Average Volume (3M)3.38M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$83.54M
Total Debt (Recent Filing)$16.21M
P/E Ratio-1.7
Next EarningsNov 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.23
Shares Outstanding118,761,192
Standard Deviation0.16
10 Day Avg. Volume5,430,560
30 Day Avg. Volume3,383,336
P/B Ratio-21.75
P/S Ratio4.83
P/CF RatioN/A
P/FCF Ratio-2.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside92.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $2.19 and its highest was $12.79 in the past 12 months.
    What is Heron Therapeutics’s market cap?
    Currently, no data Available
    When is Heron Therapeutics’s upcoming earnings report date?
    Heron Therapeutics’s upcoming earnings report date is Nov 09, 2022 which is in 42 days.
      How were Heron Therapeutics’s earnings last quarter?
      Heron Therapeutics released its earnings results on Aug 09, 2022. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.536 by -$0.014.
        Is Heron Therapeutics overvalued?
        According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Heron Therapeutics pay dividends?
          Heron Therapeutics does not currently pay dividends.
          What is Heron Therapeutics’s EPS estimate?
          Heron Therapeutics’s EPS estimate is -$0.38.
            How many shares outstanding does Heron Therapeutics have?
            Heron Therapeutics has 102,632,160 shares outstanding.
              What happened to Heron Therapeutics’s price movement after its last earnings report?
              Heron Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.536. Following the earnings report the stock price went up 15.126%.
                Which hedge fund is a major shareholder of Heron Therapeutics?
                Among the largest hedge funds holding Heron Therapeutics’s share is Fisher Asset Management LLC. It holds Heron Therapeutics’s shares valued at 505K.


                  Heron Therapeutics Stock Analysis

                  Smart ScoreNeutral
                  The Heron Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Heron Therapeutics

                  Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.

                  Similar Stocks
                  Price & Change
                  Gilead Sciences
                  Vertex Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis